| Literature DB >> 35628752 |
Toru Sakamoto1, Kenji Gotoh1, Kenyu Hashimoto2,3, Chiyoko Tanamachi4, Hiroshi Watanabe1.
Abstract
Ocular candidiasis is a critical and challenging complication of candidemia. The purpose of this study was to investigate the appropriate timing for ophthalmologic examinations, risk factors for complications of ocular lesions, and their association with mortality. This retrospective cohort study applied, using multiple logistic regression analysis and Cox regression models, to cases of candidemia (age ≥ 18 years) for patients who underwent ophthalmologic consultation. Of the 108 candidemia patients who underwent ophthalmologic examination, 27 (25%) contracted patients had ocular candidiasis, and 7 experienced the more severe condition of endophthalmitis, which included subjective ocular symptoms. In most cases, the initial ophthalmologic examination was performed within one week of the onset of candidiasis with a diagnosis of ocular candidiasis, but in three cases, the findings became apparent only after a second examination within 7-14 days after onset of candidiasis. The independent risk factor extracted for the development of ocular candidiasis was the isolation of C. albicans (OR, 4.85; 95% CI, 1.58-14.90), unremoved CVC (OR, 10.40; 95% CI, 1.74-62.16), and a high βDG value (>108.2 pg/mL) (HR, 2.83; 95% CI = 1.24-6.27). Continuous ophthalmologic examination is recommended in cases of candidemia with the above risk factors with an initial examination within 7 days of onset and a second examination 7-14 days after onset.Entities:
Keywords: (1,3)-β-D-glucan (βDG); Candida; endogenous endophthalmitis; fungal endophthalmitis; ocular candidiasis; ophthalmologic examination
Year: 2022 PMID: 35628752 PMCID: PMC9146072 DOI: 10.3390/jof8050497
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Figure 1The process of selecting and classification target cases. Gray shadow: excluded cases. The ultimate analysis included 108 cases. Twenty-seven cases of ocular candidiasis included seven probable endophthalmitis and twenty probable chorioretinitis. Eighty-one cases of non-ocular candidiasis included thirteen possible ocular candidiasis and sixty-eight cases with no sign of ocular candidiasis.
Characteristics of patients with ocular candidiasis and the intervals of ophthalmologic examinations.
| Age | Sex | Eye Symptom | Onset to | 1st Exam to | Diagnosis | Background | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| 73 | F | Poor eyesight | 0 | 3 | No | Thyroid cancer | |
| 79 | F |
| Poor eyesight | 12 | 3 | No | Stomach cancer |
| 66 | M |
| Poor eyesight | 2 | 7 |
| AML, severe neutropenia |
| 76 | M |
| Myodesopsia | 5 | 9 | No | Pharyngeal cancer |
| 69 | M |
| Poor eyesight | 4 | 4 |
| Pancreatic cancer |
| 37 | M |
| Poor eyesight | 1 | Died | No | HIV infection |
| 64 | M |
| Poor eyesight | 3 | 7 | No | Stomach cancer |
|
| |||||||
| 65 | F |
| No | 5 | 10 | No | Peritoneal cancer |
| 74 | M |
| No | 11 | 12 | No | Bile duct cancer |
| 57 | F |
| No | 3 | 9 |
| SAH |
| 75 | M |
| No | 6 | Died | No | Multiple trauma |
| 56 | F |
| No | 3 | 8 | No | Acute aortic dissection |
| 77 | F |
| No | 4 | 20 | No | Rheumatoid arthritis |
| 46 | M |
| No | 16 | Died | No | Burkitt’s lymphoma |
| 71 | M |
| No | 6 | 2 | No | Cervical abscess |
| 73 | F |
| No | 4 | Died | No | Mandibular cancer |
| 63 | F |
| No | 3 | 6 | No | Pulmonary embolism |
| 66 | M |
| No | 6 | 5 | No | SAH |
| 73 | M |
| No | 5 | 8 | No | Ischemic heart disease |
| 78 | M |
| No | 3 | 8 | No | Pancreas cystic tumor |
| 80 | M |
| No | 4 | 3 | No | Infectious endocarditis |
| 69 | F |
| No | 5 | 7 | No | Cervical cancer |
| 57 | F |
| No | 3 | Died | No | Ovarian cancer |
| 78 | M |
| No | 5 | 14 | No | Esophageal cancer |
| 81 | M |
| No | 4 | Died | No | Malignant melanoma |
| 43 | M |
| No | 3 | 7 | No | Acidophilic enteritis |
| 68 | M |
| No | 7 | 5 | No | Colon cancer |
AML, acute myeloid leukemia; HIV, human immunodeficiency virus; SAH, Sub-arachnoid hemorrhage.
Univariate analysis for the factors with ocular candidiasis in cases with candidemia.
| Ocular Candidiasis | (%) | Non-Ocular | (%) | ||
|---|---|---|---|---|---|
| Mean age ± SD | 67.1 ± 11.5 | 68.1 ± 12.8 | 0.63 | ||
| Male | 17 | 62.9% | 54 | 66.6% | 0.72 |
| Underlying diseases | |||||
| Diabetes mellitus | 5 | 18.5% | 31 | 38.2% | 0.06 |
| Hypertension | 10 | 37.0% | 36 | 44.4% | 0.50 |
| Chronic heart disease | 5 | 18.5% | 16 | 19.7% | 1.00 |
| Chronic kidney disease stage | 2 | 7.4% | 9 | 11.1% | 0.72 |
| Liver diseases | 1 | 3.7% | 10 | 12.3% | 0.28 |
| COPD | 1 | 3.7% | 3 | 3.7% | 1.00 |
| Malignancy | 15 | 55.5% | 41 | 50.6% | 0.65 |
| Hematological malignancy | 2 | 7.4% | 12 | 14.8% | 0.51 |
| Solid-organ cancer | 13 | 48.1% | 29 | 35.8% | 0.25 |
| Immunocompromised status | |||||
| Steroid therapy | 4 | 14.8% | 15 | 18.5% | 0.77 |
| Immunosuppressive agent | 1 | 3.7% | 7 | 8.6% | 0.67 |
| Chemotherapy | 9 | 33.3% | 23 | 28.4% | 0.62 |
| Neutropenia | 2 | 7.4% | 7 | 8.6% | 1.00 |
| Radiation therapy | 0 | 0.0% | 8 | 9.8% | 0.19 |
| HIV infection | 1 | 3.7% | 0 | 0.0% | 0.25 |
| Stem cell transplantation | 1 | 3.7% | 5 | 6.1% | 1.00 |
| Microbiology | |||||
|
| 18 | 66.7% | 28 | 34.6% | <0.05 |
|
| 3 | 11.1% | 24 | 29.6% | 0.07 |
|
| 3 | 4.0% | 13 | 15.0% | 0.75 |
|
| 2 | 8.0% | 3 | 3.7% | 0.59 |
|
| 0 | 0.0% | 5 | 6.5% | 0.33 |
|
| 2 | 8.0% | 4 | 5.0% | 0.62 |
| Other | 1 | 3.7% | 5 | 6.1% | 1.00 |
| Polymicrobial fungemia | 2 | 7.4% | 1 | 1.2% | 0.15 |
| Underlying conditions | |||||
| ICU admission | 11 | 40.7% | 31 | 38.2% | 0.81 |
| Surgery | 7 | 25.9% | 29 | 35.8% | 0.34 |
| Abdominal surgery | 2 | 7.4% | 16 | 19.7% | 0.23 |
| Open-heart surgery | 2 | 7.4% | 6 | 7.5% | 1.00 |
| Prior antibiotics exposure | 24 | 88.8% | 59 | 28.8% | 0.08 |
| Prior antifungal exposure | 2 | 7.4% | 14 | 17.2% | 0.34 |
| Indwelling CVC | 23 | 85.1% | 60 | 74.0% | 0.23 |
| unremovable of CVC | 5 | 18.5% | 3 | 3.7% | <0.05 |
| nterval days onset | 1.1 ± 1.6 | 2.1 ± 2.6 | |||
| TPN | 17 | 62.9% | 48 | 59.2% | 0.73 |
| Mechanical ventilation | 5 | 18.5% | 18 | 22.2% | 0.79 |
| Hemodialysis | 4 | 14.8 | 14 | 17.2 | 1.00 |
| Septic shock | 6 | 22.2% | 17 | 20.9% | 0.89 |
| Initial antifungal drugs | |||||
| Azole | 15 | 55.6% | 49 | 60.5% | 0.65 |
| Echinocandin | 9 | 33.3% | 31 | 38.3% | 0.64 |
| L-AMB | 2 | 7.4% | 1 | 1.2% | 0.15 |
| Interval days onset and administering antifungal drugs | 2.8 ± 0.38 | 2.2 ± 0.22 | 0.33 | ||
| Persistent BSI | 11 | 44.0% | 27 | 33.8% | 0.36 |
| (1,3)-β-D-glucan | <0.05 | ||||
| 30-day mortality | 10 | 37.0% | 12 | 14.8% | <0.05 |
SD, standard deviation; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; ICU; intensive care unit; CVC, central venous catheter; TPN, total parenteral nutrition; BSI, blood stream infection; L-AMB, liposomal amphotericin B.
Multivariate analysis for the factors with ocular candidiasis in cases with candidemia.
| OR | 95% CI | ||
|---|---|---|---|
|
| 4.85 | 1.58–14.90 | <0.05 |
| Unremoved CVC | 10.40 | 1.74–62.16 | <0.05 |
| (1,3)-β-D-G-glucan | 1.003 | 1.0004-1.005 | <0.05 |
OR, odds ratio; CI, confidence interval; CVC, central venous catheter.
Figure 2Kaplan−Meier curve showing the proportion of patients with ocular candidiasis in two groups determined by β-D-glucan levels. ROC curves were created for the presence of ocular lesions, and the Youden index was calculated to be 108.2. Based on this β-D-glucan value, cases were divided into two groups. The log-run test was statically significant at p < 0.05.
Univariate analysis of factors associated with 30-day mortality.
| Survivors | (%) | Death | (%) | ||
|---|---|---|---|---|---|
| Mean age ± SD | 68.1 ± 12.3 | 67.1 ± 13.7 | 0.75 | ||
| Male | 61 | 70.9% | 10 | 45.5% | <0.05 |
| Underlying diseases | |||||
| Diabetes mellitus | 29 | 33.7% | 7 | 31.8% | 0.86 |
| Hypertension | 38 | 44.2% | 8 | 36.4% | 0.50 |
| Chronic heart disease | 17 | 19.8% | 4 | 18.2% | 0.86 |
| Chronic kidney disease stage | 10 | 11.6% | 1 | 4.6% | 0.28 |
| Liver diseases | 11 | 12.7% | 0 | 0.0% | 0.11 |
| COPD | 2 | 2.3% | 2 | 9.1% | 0.18 |
| Malignancy | 44 | 51.2% | 12 | 54.6% | 0.77 |
| Hematological malignancy | 10 | 11.6% | 4 | 18.1% | 0.43 |
| Solid-organ cancer | 34 | 39.5% | 8 | 36.4% | 0.78 |
| Immunocompromised status | |||||
| Steroid therapy | 13 | 15.1% | 6 | 27.3% | 0.20 |
| Immunosuppressive agent | 5 | 5.8% | 3 | 13.6% | 0.35 |
| Chemotherapy | 24 | 27.9% | 8 | 36.3% | 0.44 |
| Neutropenia | 6 | 7.0% | 3 | 13.6% | 0.38 |
| Radiation therapy | 8 | 9.3% | 0 | 0.0% | 0.20 |
| HIV infection | 0 | 0.0% | 1 | 4.6% | 0.20 |
| Stem cell transplantation | 4 | 4.7% | 2 | 9.1% | 0.59 |
| Microbiology | |||||
|
| 36 | 41.9% | 10 | 45.5% | 0.81 |
|
| 22 | 25.6% | 5 | 22.7% | 0.78 |
|
| 13 | 15.1% | 3 | 13.6% | 0.86 |
|
| 3 | 3.5% | 2 | 9.1% | 0.30 |
|
| 4 | 4.7% | 1 | 4.6% | 0.98 |
|
| 4 | 4.7% | 2 | 9.1% | 0.41 |
| Other | 6 | 7.0% | 0 | 0.0% | 0.34 |
| Polymicrobial fungemia | 2 | 2.3% | 1 | 4.6% | 0.49 |
| Underlying conditions | |||||
| ICU admission | 35 | 40.7% | 7 | 31.8% | 0.47 |
| Surgery | 31 | 36.1% | 5 | 22.7% | 0.22 |
| Abdominal surgery | 14 | 16.3% | 4 | 18.2% | 0.83 |
| Open-heart surgery | 8 | 9.41% | 0 | 0.0% | 0.20 |
| Prior antibiotics exposure | 65 | 75.6% | 18 | 81.8% | 0.52 |
| Prior antifungal exposure | 12 | 14.0% | 4 | 18.2% | 0.62 |
| Indwelling CVC | 67 | 77.9% | 16 | 72.7% | 0.61 |
| Unremovable of CVC | 2 | 2.3% | 6 | 27.3% | <0.05 |
| Interval days onset | 1.8 ± 0.3 | 2.5 ± 0.8 | 0.39 | ||
| TPN | 51 | 59.3% | 14 | 63.6% | 0.70 |
| Mechanical ventilation | 19 | 22.1% | 4 | 18.2% | 0.68 |
| Hemodialysis | 10 | 11.6 | 1 | 4.6% | 0.28 |
| Septic shock | 16 | 14.8% | 7 | 6.5% | 0.19 |
| Initial antifungal drugs | |||||
| Azole | 11 | 50.0% | 53 | 61.6% | 0.32 |
| Echinocandin | 10 | 45.5% | 30 | 34.9% | 0.36 |
| L-AMB | 1 | 4.6% | 2 | 2.3% | 0.59 |
| Interval days onset and administering antifungal drugs | 2.4 ± 0.21 | 1.8 ± 0.42 | 0.19 | ||
| Persistent BSI | 13 | 65% | 25 | 29.4% | <0.05 |
| (1,3)-β-D-glucan | <0.05 | ||||
| Ocular candidiasis | 17 | 19.8% | 10 | 45.5% | <0.05 |
SD, standard deviation; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; ICU, intensive care unit; CVC, central venous catheter; TPN, total parenteral nutrition; BSI, blood stream infection; L-AMB, liposomal amphotericin B.
Multivariate analysis of the factors associated with 30-day mortality.
| OR | 95% CI | ||
|---|---|---|---|
| Female | 1.75 | 0.52–5.81 | 0.35 |
| Unremoved CVC | 17.76 | 2.18–144.38 | <0.05 |
| Persistent BSI | 3.17 | 0.79–12.70 | 0.10 |
| (1,3)-β-D-G-glucan | 1.00 | 0.90–1.00 | 0.22 |
| Ocular candidiasis | 1.98 | 0.54–7.34 | 0.30 |
R, odds ratio; CI, confidence interval; CVC, central venous catheter; BSI, blood stream infection.